Efficacy of Pentoxifylline on Chronic Kidney Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To study whether pentoxifylline has additive renoprotective effect in patients taking ARB
Condition or disease
Chronic Kidney Disease
Drug: pentoxifylline (drug)
In patients with CKD and serum creatinine 1.3~6.0 md/gl, having taken losartan 100 mg/day for at least 3 months, with stable renal function, will be recruited to a randomized open-label trial. Patients taking pentoxifylline or not will be compared for their spot urinary proteinuria, estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups in a 2-year study. Add-on pentoxifylline in control group in the same dose as in treat group will be performed to observe the renoprotective effect if any protective potential is demonstrated in the end of maintenance 12 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chronic kidney disease with serum creatinine 1.3~6.0 mg/dl
History of allergy to pentoxifylline
Females are nursing or pregnant
Unable to stop chronic immunosuppressive therapy, NSAID
Congestive heart failure (New York Heart Association functional class III or IV)
Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form
Cerebral hemorrhage within the past 6 months prior to signing the informed consent form
Retinal hemorrhage within the past 6 months prior to signing the informed consent form
Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma)
Severe uncontrolled hypertension with SBP > 220 mmHg and/or DBP > 115 mmHg
Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 2 times the upper limit of the normal range